SCHEMBL43075

SCHEMBL43075

NC(=O)C1(c2ccccc2F)CCCC1

nearest known ligand 0.65

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 6/20 0.65
OPRL1 P41146 2/20 0.54
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
AKR1C1 Q04828 1/20 0.44
MAPT P10636 2/20 0.43
THRB P10828 1/20 0.43
GAA P10253 1/20 0.42
P2RX7 Q99572 1/20 0.42
HTT P42858 1/20 0.41
RECQL P46063 1/20 0.41
PSEN1 P49768 1/20 0.41
PSEN2 P49810 1/20 0.41
APH1B Q8WW43 1/20 0.41
NCSTN Q92542 1/20 0.41
APH1A Q96BI3 1/20 0.41
PSENEN Q9NZ42 1/20 0.41
ELOVL1 Q9BW60 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3842808 0.98 HDAC4 (0.63) HDAC4OPRL1ALDH1A1LMNAAKR1C1
SCHEMBL10002458 0.96 HDAC4 (0.60) HDAC4OPRL1ALDH1A1LMNAAKR1C1
SCHEMBL4744830 0.94 HDAC4 (0.57) HDAC4OPRL1ALDH1A1LMNAMAPT
Hydrochloric Acid SCHEMBL8642813 0.85 OPRL1 (0.49) HDAC4OPRL1ALDH1A1LMNAELOVL1
SCHEMBL3184587 0.83 HDAC4 (0.67) HDAC4ALDH1A1LMNAAKR1C1MAPT
SCHEMBL31580968 0.83 HDAC4 (0.67) HDAC4ALDH1A1LMNAAKR1C1MAPT
SCHEMBL18742673 0.82 HDAC4 (0.62) HDAC4OPRL1LMNAELOVL1
SCHEMBL29567033 0.81 HDAC4 (0.65) HDAC4ALDH1A1LMNAAKR1C1MAPT
SCHEMBL2867660 0.81 HDAC4 (0.65) HDAC4ALDH1A1LMNAAKR1C1MAPT
SCHEMBL4805485 0.80 HDAC4 (0.63) HDAC4ALDH1A1LMNAAKR1C1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240115553-A1 COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY AZEVAN PHARMACEUTICALS, INC. (US) 2024-04-11 US claimed
EP-3122743-B1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AZEVAN PHARMACEUTICALS INC (US) 2022-11-09 EP claimed
US-11319306-B2 Compositions and methods for treating neurodegenerative diseases AZEVAN PHARMACEUTICALS, INC. (US) 2022-05-03 US claimed
US-20240115553-A1 COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY AZEVAN PHARMACEUTICALS, INC. (US) 2024-04-11 US disclosed
US-20230123729-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AZEVAN PHARMACEUTICALS INC (US) 2023-04-20 US disclosed
US-11628160-B2 Compositions and methods for treating brain injury AZEVAN PHARMACEUTICALS, INC. (US) 2023-04-18 US disclosed
EP-3122743-B1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AZEVAN PHARMACEUTICALS INC (US) 2022-11-09 EP disclosed
US-11319306-B2 Compositions and methods for treating neurodegenerative diseases AZEVAN PHARMACEUTICALS, INC. (US) 2022-05-03 US disclosed
US-10953001-B2 Methods for treating post traumatic stress disorder AZEVAN PHARMACEUTICALS, INC. (US) 2021-03-23 US disclosed
EP-3351104-B1 COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER AZEVAN PHARMACEUTICALS INC (US) 2020-12-09 EP disclosed
US-20200276167-A1 COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY AZEVAN PHARMACEUTICALS INC (US) 2020-09-03 US disclosed
US-20160339006-A1 METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-11-24 US disclosed
US-9376424-B2 Methods for treating post traumatic stress disorder AZEVAN PHARMACEUTICALS, INC. (US) 2016-06-28 US disclosed
WO-2015148962-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AZEVAN PHARMACEUTICALS, INC. (US) 2015-10-01 WO disclosed
CN-103269584-A Methods for treating post-traumatic stress disorder AZEVAN PHARMACEUTICALS INC 2013-08-28 CN disclosed
EP-2587919-A1 METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER Azevan Pharmaceuticals, Inc. (US) 2013-05-08 EP disclosed
US-20130109666-A1 METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER AZEVAN PHARMACEUTICALS, INC. (US) 2013-05-02 US disclosed
WO-2012003436-A1 METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER AZEVAN PHARMACEUTICALS, INC. (US) 2012-01-05 WO disclosed
US-20100016274-A1 BETA-LACTAM CANNABINOID RECEPTOR MODULATORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-01-21 US disclosed
US-20090170825-A1 BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS AZEVAN PHARMACEUTICALS, INC. 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240115553-A1 COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY FABP7, PYGB, CHAT HDAC4 435/4885OPRL1 2712/4885ALDH1A1 1429/4885
US-10953001-B2 Methods for treating post traumatic stress disorder GPX4, CRH, TXN HDAC4 369/4885OPRL1 99/4885ALDH1A1 1136/4885
US-20100016274-A1 BETA-LACTAM CANNABINOID RECEPTOR MODULATORS CNR2, CNR1, FAAH2 HDAC4 2176/4885OPRL1 28/4885ALDH1A1 1118/4885
US-20200276167-A1 COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY FABP7, PYGB, CHAT HDAC4 435/4885OPRL1 2712/4885ALDH1A1 1429/4885
US-20090170825-A1 BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS GABBR1, GABBR2, ALAD HDAC4 2552/4885OPRL1 488/4885ALDH1A1 335/4885
US-11319306-B2 Compositions and methods for treating neurodegenerative diseases HTT, AVPR2, AVPR1B HDAC4 598/4885OPRL1 38/4885ALDH1A1 3383/4885
US-20230123729-A1 COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES HTT, AVPR2, AVPR1B HDAC4 598/4885OPRL1 38/4885ALDH1A1 3383/4885
US-11628160-B2 Compositions and methods for treating brain injury FABP7, PYGB, CHAT HDAC4 435/4885OPRL1 2712/4885ALDH1A1 1429/4885
US-20130109666-A1 METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER GPX4, CRH, TXN HDAC4 369/4885OPRL1 99/4885ALDH1A1 1136/4885
US-20160339006-A1 METHODS FOR TREATING POST TRAUMATIC STRESS DISORDER GPX4, CRH, TXN HDAC4 369/4885OPRL1 99/4885ALDH1A1 1136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.